IL6 and type 2 diabetes mellitus: Inflammatory markers and other haemostatic factor (IL-6, TNF alpha, leptin, s-ICAM, platelet aggregation) were unaffected by both treatment, despite the great improvement in glucose profile, Such persistence in inflammation is probably implicated in the poor reduction in cardiovascular disease despite glucose control in type 2 diabetes patients [19].